Fig. 1

BVM analogs are active against HIV-1 subtype B, NL4-3. a Structure of parental compound Bevirimat (BVM) and its C-28 modified analogs CV-8611, CV-8612, and CV-8613. HEK-293T cells were transfected with the HIV-1 subtype B clone NL4-3. Cells were treated with 10 nM and 100 nM of the BVM analogs or with DMSO only. b The virion-associated CA and CA-SP1 were detected by immunoblotting. The gel image shown here is representative of three independent experiments. Quantification of % CA-SP1 relative to total CA + CA-SP1 is presented in the graphs. c The viruses produced from MI-treated HEK-293 T cells were quantified. TZM-bl cells were infected with p24 normalized HIV-1 viruses for 48 h. The cells were lysed and assayed for luciferase activity. Quantitative data for levels of infectivity relative to the DMSO control-treated sample is shown. Error bars indicate standard deviations from three independent experiments. The asterisks indicate significant differences (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001) and ns indicates not significant